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Stephen D. Skaper* and Pietro GiustiAbstract
Background: Toll-like receptor (TLR) activation on microglia and astrocytes are key elements in neuroinflammation
which accompanies a number of neurological disorders. While TLR activation on glia is well-established to up-regulate
pro-inflammatory mediator expression, much less is known about how ligand engagement of one TLR may affect
expression of other TLRs on microglia and astrocytes.
Methods: In the present study, we evaluated the effects of agonists for TLR2 (zymosan), TLR3 (polyinosinic-polycytidylic
acid (poly(I:C)), a synthetic analogue of double-stranded RNA) and TLR4 (lipopolysaccaride (LPS)) in influencing expression
of their cognate receptor as well as that of the other TLRs in cultures of rat cortical purified microglia (>99.5 %) and
nominally microglia-free astrocytes. Elimination of residual microglia (a common contaminant of astrocyte cultures)
was achieved by incubation with the lysosomotropic agent L-leucyl-L-leucine methyl ester (L-LME).
Results: Flow cytometric analysis confirmed the purity (essentially 100 %) of the obtained microglia, and up
to 5 % microglia contamination of astrocytes. L-LME treatment effectively removed microglia from the latter
(real-time polymerase chain reaction). The three TLR ligands robustly up-regulated gene expression for pro-inflammatory
markers (interleukin-1 and interleukin-6, tumor necrosis factor) in microglia and enriched, but not purified, astrocytes,
confirming cellular functionality. LPS, zymosan and poly(I:C) all down-regulated TLR4 messenger RNA (mRNA) and
up-regulated TLR2 mRNA at 6 and 24 h. In spite of their inability to elaborate pro-inflammatory mediator output, the
nominally microglia-free astrocytes (>99 % purity) also showed similar behaviours to those of microglia, as well as
changes in TLR3 gene expression. LPS interaction with TLR4 activates downstream mitogen-activated protein kinase
and nuclear factor-κB signalling pathways and subsequently causes inflammatory mediator production. The effects of
LPS on TLR2 mRNA in both cell populations were antagonized by a nuclear factor-κB inhibitor.
Conclusions: TLR2 and TLR4 activation in particular, in concert with microglia and astrocytes, comprise key elements in
the initiation and maintenance of neuropathic pain. The finding that both homologous (zymosan) and heterologous
(LPS, poly(I:C)) TLR ligands are capable of regulating TLR2 gene expression, in particular, may have important implications
in understanding the relative contributions of different TLRs in neurological disorders associated with neuroinflammation.
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Inflammation is the body’s attempt at self-protection to
remove harmful stimuli, including damaged cells, irri-
tants and pathogens—and initiate the healing process.
Activation of the innate immune system is an integral
aspect of the response to inflammation. When pro-
longed, however, inflammation can become adversarial.
Inflammation and neurological diseases are intimately
connected, with ever-growing evidence pointing to its
being a key feature in the pathobiology of neuropathic
pain, chronic neurodegenerative diseases, brain ische-
mia, spinal cord injury, traumatic brain injury, some
neuropsychiatric disorders [1–5] and possibly even aut-
ism spectrum disorder [6]. Microglia, the resident
macrophage population in the CNS—along with astrocy-
tes—constitute principal players in neuroinflammatory
responses [7–13].
The innate immune system relies on a set of germ-line
encoded receptors that recognize conserved molecular
patterns found only in microorganisms. This large family of
so-called pattern recognition receptors includes the Toll-
like receptors (TLRs), considered as crucial environmental-
sensing molecular motifs for pathogen-associated molecu-
lar patterns, which are linked with microbial pathogens or
cell stress, as well as danger-associated molecular patterns
released during cell damage [14–17]. Rodent microglia
express mRNA for all of the recently identified TLRs,
TLR1-9, used for recognition of bacterial and viral molecu-
lar patterns, whereas other neural cells (e.g. astrocytes)
express a more limited TLR repertoire [15, 18]. TLR signal-
ling pathways have been implicated in neurodegenerative
disorders [19], including motor neuron disease [20], as well
as in pathological pain [21–24].
Recent studies indicate that microglia-free astrocytes,
unlike microglia, are unresponsive to TLR engagement
in terms of pro-inflammatory molecule output [7, 8, 25].
Further, several of these reports have suggested that
microglial cells express a heightened responsivity to TLR
agonists when cultured in the presence of astrocytes [7,
8]. While the literature contains numerous examples of
astrocyte response to TLR activation, these cell prepara-
tions more often than not contain up to 5 % contaminat-
ing microglia (e.g. [26]), which can confound the effects
observed [27–29]. However, whether or not these obser-
vations extend also to the ability of glia TLRs to regulate
their own expression, or that of other TLR subtypes,
remains to be fully explored. Given that multiple TLRs
may be activated in neuropathological settings, the up-
or down-regulation of one TLR consequent to engage-
ment of another may have important disease implications.
In order to address this question, we interrogated purified
cortical microglia and astrocytes for their capacity to ex-
press TLR2, TLR3 and TLR4 mRNA and protein upon
treatment with either the cognate ligand or that of one ofthe other TLRs. Our results show a complex pattern of
TLR regulation in microglia and, in addition, the capacity
of nominally microglia-free astrocytes to both express and
respond to TLR agonists in a nuclear factor-κB (NF-κB)-
dependent manner.
Methods
Tissue culture media, antibiotics, fetal calf serum (FCS)
and NP40 cell lysis buffer (10×) were purchased from
Life Technologies (San Giuliano Milanese, Italy); lipopo-
lysaccaride (LPS) (Ultra-Pure LPS-EB from E. coli
0111:B4 strain), zymosan, Pam3CSK4 (VacciGrade™) and
polyinosinic-polycytidylic acid (poly(I:C)) (high molecular
weight) were from InvivoGen (Cayla-Invivogen Europe,
Toulouse, France); BD CytoFix/CytoPerm and CytoFix
were from BD Biosciences (SACCO srl, Cadorago (CO),
Italy); Ro-106-9920 (Tocris-Cookson, Space Import–export
srl, Milan, Italy); poly-L-lysine hydrobromide (mol wt
70,000–150,000), papain, DNase I (bovine pancreas),
trypsin inhibitor, L-leucyl-L-leucine methyl ester (L-
LME), SB202190, protease inhibitor cocktail, Pefabloc®
SC (100 mM), LPS from E. coli 026:B6 (<5 % protein
impurities), polymyxin B and all other biochemicals
were purchased from Sigma-Aldrich (Milan, Italy) un-
less noted otherwise; Falcon tissue culture plasticware
was purchased from BD Biosciences. Sterilin petri
plastic dishes (10 cm Ø) were obtained from Sarstedt
(Verona, Italy).
Cell culture
Mixed glial cell cultures from cortex were prepared from
postnatal day 1–2 rat pups (strain: CD) as described pre-
viously [30]. Experiments were performed in accordance
with the National Institutes of Health guidelines for the
care and use of laboratory animals and those of the Ital-
ian Ministry of Health (D.L. 116/92), and were approved
by the Institutional Animal Care and Use Committee.
Tissue dissociates were plated in 75-cm2 poly-L-lysine-
coated tissue culture flasks at a density of 1.5 brains per
flask and grown in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM) with 2 mM glutamine, 100
units/ml penicillin/50 μg/ml streptomycin, 50 μg/ml
gentamicin and 10 % (vol/vol) FCS. Culture medium was
changed after 24 h. Upon reaching confluency (approxi-
mately 7 days later), microglia were dislodged by shaking
the flasks at 200 rpm for 1 h (37 °C). The culture superna-
tants enriched in microglia were transferred to plastic
Petri dishes (Sterilin) and incubated for 45 min at 37 °C
(5 % CO2, 95 % air) to allow differential adhesion of
microglia. Adherent microglia (>99.9 % purity) were
mechanically scraped into culture medium and replated in
this medium on poly-L-lysine-coated 96-well microwell
culture plates or 24-well multiwall plates (50,000 and
250,000 cells per well, respectively). The remaining cell
Table 1 Primer pairs used in this study
Gene target Primer name Sequence
GAPDH GAPDH For 5′-CAAGGTCATCCATGACAACTTTG-3′
GAPDH Rev 5′-GGGCCATCCACAGTCTTCTG-3′
IL-1ß IL-1ß For 5′-TGTGGCAGCTACCTATGTCT-3′
IL-1ß Rev 5′-GGGAACATCACACACTAGCA-3′
TNF-α TNF-a For 5′-CATCTTCTCAAAACTCGAGTGACAA-3′
TNF-a Rev 5′-TGGGAGTAGATAAGGTACAGCCC-3′
IL-6 IL-6 For 5′-TCACAGAAGGAGTGGCTAAGG-3′
IL-6 Rev 5′-GCTTAGGCATAGCACACTAGG-3′
TLR2 TLR2 For 5′-TCCATGTCCTGGTTGACTGG-3′
TLR2 Rev 5′-AGGAGAAGGGCACAGCAGAC-3′
TLR4 TLR4 For 5′-GATTGCTCAGACATGGCAGTTTC-3′
TLR4 Rev 5′-CACTCGAGGTAGGTGTTTCTGCTAA-3′
TLR3 TLR3 For 5′-TGAAAACTACGGCGATGCAG-3′
TLR3 Rev 5′-AGGCAGTTTTACTTCCCCGA-3′
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microglia, flow cytometry using cell type-specific anti-
bodies). For some experiments, the astrocyte monolayers
were depleted of residual microglia using a 60-min expos-
ure (50 mM) to the lysosomotropic agent L-LME [27], as
described previously [7, 8]. Astrocyte plating densities
were the same as used for microglia.
Culture treatments
Microglia or astrocyte cultures were treated with one of the
following TLR ligands: 100 ng/ml LPS-EB Ultra-Pure ('LPS')
(a selective agonist for TLR4 with no LPS-independent ac-
tivity); 10 μg/ml zymosan (TLR2 agonist) [31]; 50 μg/ml
poly(I:C) (a synthetic analogue of double-stranded RNA
which activates TLR3) [32]. Agonists were added in
DMEM+ 10 % FCS. Cells were treated for 6 or 24 h for
gene expression and flow cytometry (FCM) analysis.
FCM
Monolayers of purified cortical microglia and astrocytes
(±L-LME treatment) were washed with phosphate-
buffered saline (PBS), scraped into PBS and the cells pel-
leted by centrifugation (200g, 5 min). Samples were fixed
with BD CytoFix or fixed/permeabilized with BD Cyto-
Fix/CytoPerm at 4 °C for 20 min, depending on whether
the antigen of interest was located on the cell surface or
intracellularly. Purified microglia and enriched astrocytes
were immunophenotypically characterized by FCM using
the following primary antibodies against rat markers:
Alexa Fluor® 647 mouse anti-glial fibrillary acidic protein
(GFAP) (Cell Signaling Technology Europe, Leiden, The
Netherlands); rabbit anti-ionized calcium-binding adapter
molecule 1 (Iba1) (Wako, Richmond, VA, USA); rabbit
anti-TLR2 (sc-10739) polyclonal antibody raised against
amino acids 180–354 of TLR2 of human origin (Santa
Cruz Biotechnology, Heidelberg, Germany); rabbit anti-rat
TLR3 (sc-28999) polyclonal antibody raised against amino
acids 26–325 mapping within an N-terminal extracellular
domain of TLR4 of mouse origin (Santa Cruz); rabbit
anti-rat TLR4 (sc-30002) polyclonal antibody raised
against amino acids 339–638 mapping within an N-
terminal extracellular domain of TLR4 of mouse origin
(Santa Cruz); AlexaFluor® 647 mouse monoclonal anti-
body IgG1 isotype control (Cell Signaling); AlexaFluor®488
anti-rabbit or anti-mouse secondary antibodies (II Ab)
(Life Technologies). For staining, 200,000 cells were incu-
bated with the selected antibody in PBS containing 0.5 %
bovine serum albumin (BSA) (Sigma-Aldrich) for 15 min
at room temperature. For indirect labelling, the samples
were washed with 0.5 % BSA solution and then stained
with appropriate secondary antibody. In parallel, samples
labelled with isotype or secondary conjugated antibodies
were prepared as negative controls. Data were acquired
using FACSCanto II Flow cytometer (BD Biosciences) andthen analysed with Summit 4.3 (DAKO-Beckman Coulter)
and FACSDiva v6.1.3 (BD Biosciences) softwares. The ex-
pression of GFAP and Iba1 was reported as geometric
mean fluorescent intensity (MFI) ± standard deviation
(SD) and percentage of positive cells while data of TLRs
were expressed as the ratio of relative MFI (rMFI) values
derived from resting (Ctr + 10 % FBS) and primed (+TLR
agonist) cultures for each TLR normalized to its II AB-
matched negative control (relative MFI). Assuming that a
ratio equal to 1 was observed in the case of undetectable
difference in primed cells compared to resting samples,
values greater or less than 1 were indicative of an increase
or decrease in TLR expression, respectively, in samples
treated with TLR agonists.Quantitative Real-Time-PCR (qRT-PCR)
Total RNA was extracted from cells using the ReliaPrep™
RNA Cell Miniprep System (Promega), according to the
manufacturer’s instructions. RNA integrity and quantity
were determined by RNA 6000 Nano assay in an Agilent
BioAnalyser. Samples were reverse transcribed with
Superscript III reverse transcriptase (Life Technologies).
The RT-PCR reaction was performed as described previ-
ously using a MX 3000P (Stratagene) [7]. Primer se-
quences are listed in Table 1. Amounts of each gene
product were calculated using linear regression analysis
from standard curves, demonstrating amplification effi-
ciencies ranging from 90 to 100 %. Dissociation curves
were generated for each primer pair showing single prod-
uct amplification. In the figures, the term ‘fold-increase’ is
defined as the cDNA ratio between target gene and refer-
ence gene (GAPDH) normalized to untreated control.
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Cell monolayers were washed with cold PBS and to each
well was then added 40 μl of lysis solution (890 μl NP40
cell lysis buffer (Life Technologies, 100 μl protease in-
hibitor cocktail (Sigma-Aldrich), 10 μl of 0.1 M Pefabloc
SC (Fluka)). After 30 min on ice, the lysates were col-
lected and cleared by centrifugation at 13,000 rpm for
10 min (Microfuge® 22R centrifuge, Beckman Coulter).
The supernatants were retained and stored at −80 °C.
Protein content of lysates was determined using the
BCA Protein Assay Reagent Kit (Pierce) following the
manufacturer’s protocol. Protein samples (10 μg) were
separated on a Mini-PROTEAN® Precast Gel (Biorad)
with a 4–15 % gradient for 90 min at 140 V. Proteins
were electrophoretically transferred onto polyvinylidene
difluoride (Merck Millipore) membranes overnight at 4 °C
at 25 V. Membranes were then blocked with 3 % BSA and
incubated overnight at 4 °C with one of the following
primary antibodies: mouse monoclonal against β-actin
(working dilution 1:25000; Sigma-Aldrich); rabbit poly-
clonal against rat TLR4 (working dilution 1:300; Santa
Cruz Biotechnology); rabbit polyclonal against rat CD14
(working dilution 1:200; Santa Cruz Biotechnology);
rabbit polyclonal against rat MD2 (working dilution
1:1000; Abcam®). The membranes were then washed
and incubated 1 h with the appropriate secondary
antibody (goat anti-rabbit IgG horseradish peroxidase-
conjugated or goat anti-mouse IgG horseradish
peroxidase-conjugated, Merck Millipore) diluted 1:4000.
Blots were developed using an enhanced chemilumines-
cence substrate (Sigma-Aldrich) and immunoreactivity
visualized utilizing the VersaDoc Imaging System. Pro-
tein expression was normalized to β-actin for band
density quantification.
Immunofluorescence
Enriched astrocytes were seeded on poly-L-lysine-coated
12-mm diameter cover glasses (Menzel-Gläser, Menzel
GmbH, Germany) placed in the wells of a 12-well plate
(500,000 cells per well) and allowed to adhere overnight.
The next day, the cells were treated with 50 mM L-LME
for 1 h and allowed to recover for 1 day in L-LME-free
medium. Cells were fixed with 4 % paraformaldehyde
(Sigma-Aldrich), at 4 °C for 30 min. After fixation, cells
were washed 3 × 10 min in PBS, pH 7.4. Cells were then
permeabilized and blocked with PBS/0.05 % Triton X-
100/10 % normal goat serum for 1 h at room temperature,
after which time they were incubated overnight with one
of the following primary antibodies: mouse monoclonal
anti-GFAP antibody (1:400 dilution, Sigma-Aldrich),
rabbit polyclonal anti-TLR4 antibody (1:200 dilution,
Santa Cruz), or LPS conjugated with Alexa Fluor® 488
(1:200 dilution, Wako, Japan). Cells were washed 3 × 10 min
with PBS and subsequently incubated for 1 h at roomtemperature with Alexa Fluor® 488 goat anti-rabbit IgG or
Alexa Fluor® 555 goat anti-mouse IgG secondary antibody
(1:500). Nuclei where visualized by incubating for 2 min
with DAPI (Boehringer Mannheim, Germany). Cover
glasses were mounted onto glass slides using Fluoromount-
G (Southern Biotech, USA), and images were acquired on
a Leica DMI4000 B microscope equipped for immuno-
fluorescence (Leica Microsystems GmbH, Wetzlar,
Germany) using a Leica DFC 480 digital camera (Leica
Microsystems GmbH, Wetzlar, Germany).
Cytokine ELISA assays
Cells were stimulated to release pro-inflammatory medi-
ators in medium containing TLR ligand as indicated in
the respective figure legend. Cell supernatants were
collected and stored at −20 °C until the day of assay. Cell
lysates were prepared as described previously [8].
Interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α
(TNF-α) released into the culture medium (and IL-1β in
cell lysates) were analysed using commercially available
ELISA kits according to the manufacturer’s instructions
(Antigenix America, Huntington Station, NY, USA).
Standards with known amounts of IL-1β, IL-6 or TNF-α
were used to convert values into absolute concentrations
of cytokine in pg/culture well.
Statistical analysis
Data are given as mean ± SEM. Statistical analyses to de-
termine group differences were performed by one-way
analysis of variance, followed by Dunnett’s or Bonferroni’s
post-hoc test for comparisons involving more than two
data groups. Significance was taken at p < 0.05.
Results
Flow cytometric analysis of glia cell populations from
cortex
By flow cytometric analysis, mixed glial cell cultures
were seen to be enriched in astrocytes as demonstrated
by the high expression level of GFAP and large cell size
(forward scatter, FSC) (Fig. 1a, left and right panels, re-
spectively). A minimal contamination of 10 % microglia
was discriminated based on positive expression of Iba1
marker (Fig. 1a, middle panel) and lower value of cell
size (FSC) and granularity (side scatter, SSC) (Fig. 1c).
Mechanical dislodgment by plate shaking was efficacious
to obtain a population of highly purified cells expressing
Iba1 (essentially 100 %) but not GFAP (0 %) (Fig. 1b,
middle and left panels, respectively) while the cultures of
post-shaken (‘enriched’) astrocytes contained >95 %
GFAP+ cells with a residual (2–5 %) subset of Iba1+ cells
(Fig. 1c, left and middle panels, respectively). The posi-
tivity of samples for GFAP and Iba1 expression was
assessed by comparing the fluorescence intensity of
Fig. 1 Immunophenotypical characterization by FCM of mixed glial cultures (a), microglia (b) and astrocytes (c) purified by mechanical
dislodgment and differential attachment. Data are expressed as percentage (%) of positives ± SD and mean fluorescent intensity (MFI) ± SD
for each marker compared to the corresponding isotype or II AB-matched negative sample (d). Microglia and astrocytes were further
characterized by cell size (forward scatter, FSC) and granularity (side scatter, SSC)
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matched negative controls (Fig. 1d).
TLR agonist-dependent pro-inflammatory profile of
purified microglia
Rat cortical microglia responded to TLR2, TLR3 and
TLR4 ligands (LPS, zymosan and (poly(I:C)), respect-
ively) after 6 h with a robust up-regulation of mRNA for
the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α
(Fig. 2a–c, left columns). These mRNA levels remained
elevated at 24 h, albeit reduced compared to 6 h (Fig. 2a–c,right columns). Changes in gene expression were accom-
panied by the corresponding cytokine product in the cul-
ture medium at both 6 and 24 h (Tables 2, 3 and 4). The
results confirm cellular functionality (see also [7, 18]). Zy-
mosan depleted is a Saccharomyces cerevisiae cell wall
preparation treated with hot alkali to remove all its TLR-
stimulating properties (InvivoGen). Zymosan depleted ac-
tivates Dectin-1 (which is also expressed in microglia) but
not TLR2. Zymosan depleted, up to a concentration of
100 μg/ml, failed to elicit cytokine gene changes or protein
release from microglia (data not shown).
Fig. 2 TLR agonists up-regulate pro-inflammatory cytokine gene expression at 6 and 24 h in purified rat cortical microglia. Cells were challenged
with a LPS (100 ng/ml); b zymosan (10 μg/ml); c poly(I:C) (50 μg/ml) and processed after 6 and 24 h for IL-1β, IL-6 and TNF-α mRNA expression
by RT-PCR. Data are means ± SEM (triplicate culture wells) normalized to GAPDH levels and are representative of three experiments. **p < 0.01 and
***p < 0.001 vs control (‘Ctr’)
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enriched and purified astrocytes
Rodent primary astrocyte cell cultures prepared by
standard protocols generally contain variable, small per-
centages (up to 5 %) of contaminating microglia [28]. As
inflammatory mediator output from enriched astrocytes
is dependent on the presence of residual microglia [7, 8,
25, 29], we used the lysosomotropic agent L-LME [33]
to deplete the remaining microglia [7, 8, 27, 34, 35](Additional file 1: Figure S1). While LPS, zymosan and
poly(I:C) markedly up-regulated mRNA for IL-1β, IL-6
and TNF-α after 6 h, parallel L-LME-treated cultures
showed little, if any, response (Fig. 3). Changes in gene
expression were again accompanied by increased
amounts of the corresponding cytokine product in the
culture medium (or intracellularly, in the case of IL-1β),
with L-LME-treated astrocytes showing very little output
(Tables 2, 3 and 4) (see also [7, 8]).
Table 2 TLR agonists up-regulate TNF-α release at 6 and 24 h in purified rat cortical microglia and enriched, but not microglia-depleted,
astrocytes
Treatment Microglia (pg TNF-α/well) Astrocytes (pg TNF-α/well)
- - - L-LME - - - L-LME
6 h 24 h 6 h 6 h 24 h 24 h
Control 0 0 0 0 0 0
LPS 272.4 ± 5.7 243.6 ± 3.0 469.4 ± 4.3 6.7 ± 6.7 378.0 ± 2.4 0
Zymosan 307.7 ± 8.9 303.5 ± 5.6 607.4 ± 25.6 34.6 ± 6.9 622.0 ± 89.1 15.7 ± 7.8
Poly(I:C) 209.3 ± 7.2 195.3 ± 10.0 287.4 ± 8.4 11.2 ± 2.4 216.7 ± 4.4 0
Purified microglia and enriched or purified (L-LME-treated) astrocytes were challenged with LPS (100 ng/ml), zymosan (10 μg/ml) or poly(I:C) (50 μg/ml) and
processed after 6 and 24 h for TNF-α release into the culture medium by ELISA. Data are means ± SEM (n = 3). Note the lack of astrocyte responsiveness
after L-LME
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microglia
The ability of TLR ligation to influence TLR subtype ex-
pression in CNS glia remains to be explored. To address
this question, we incubated purified cortical microglia
with LPS, zymosan or poly(I:C) and evaluated TLR
mRNA expression by RT-PCR after 6 or 24 h. LPS treat-
ment significantly decreased or increased, respectively,
TLR4 and TLR2 gene levels at both time points (Fig. 4).
In contrast, TLR3 gene expression was unchanged at 6 h
and significantly reduced at 24 h. Zymosan treatment of
microglia likewise produced significant decreases and in-
creases in TLR4 and TLR2 mRNA levels, respectively, at
6 and 24 h (Fig. 5), while also significantly lowering
levels of TLR3 mRNA at 6 and 24 h. Engagement of
TLR3 with poly(I:C) produced somewhat different re-
sults: TLR4 mRNA was decreased at 6 h only, TLR2 sig-
nificantly elevated at 6 and 24 h, and no change in TLR3
gene at either time point (Fig. 6).
TLR agonists regulate TLR subtype gene expression in
purified astrocytes
TLR4, together with the accessory protein MD2 and co-
receptor CD14, forms a complex that binds LPS to
transmit an intracellular signal [36–38]. Given the lack
of responsiveness of purified astrocytes to TLR4 ligation
in terms of pro-inflammatory cytokine induction, we
asked whether or not these cells express the relevantTable 3 TLR agonists up-regulate IL-1β intracellular content at 6 and
microglia-depleted, astrocytes
Treatment Microglia (pg IL-1β/well)
- - -
6 h 24 h 6 h
Control 16.0 ± 1.0 0 62.6 ±
LPS 1711.7 ± 63.9 878.1 ± 30.2 5150.4 ±
Zymosan 2036.2 ± 53.9 1382.6 ± 29.1 6910.8 ±
Poly(I:C) 1710.0 ± 125.1 631.1 ± 41.7 3911.5 ±
Purified microglia and enriched or purified (L-LME-treated) astrocytes were challeng
processed after 6 and 24 h for intracellular IL-1β content by ELISA. Data are means
IL-1β content of the corresponding culture media samples were <5 % of the intracereceptor components. Western blot analysis using spe-
cific antibodies against TLR4, CD14 and MD2 demon-
strated comparable levels of protein expression between
enriched and purified astrocytes (Fig. 7a). Given that the
enriched astrocytes contain a small number of microglia
(3–4 % on average), it is not unexpected that removal of
this component by L-LME would result in a visibly dif-
ferent level of component protein expression on West-
ern blot. Indeed, lysates from an equivalent number of
microglia (10,000) to be expected in 250,000 enriched
astrocytes, subjected to Western blot analysis for TLR2,
TLR3 and TLR4 failed to evidence a detectable signal
(Additional file 1: Figure S3). Confocal microscopy re-
vealed co-expression of GFAP and TLR4 in astrocyte-
enriched as well as in L-LME-purified astrocytes
(Fig. 7b). Moreover, a fluorescent conjugate of LPS was
utilized to show that LPS undergoes binding and trans-
port in astrocytes after a 30-min incubation and co-
localizes with GFAP (Fig. 7c).
Given the general lack of responsiveness of purified as-
trocytes to TLR ligands in terms of pro-inflammatory
cytokine induction, we then asked whether or not these
cells possessed the capability to react to TLR ligation at
the level of TLR expression. Enriched and L-LME-
purified astrocytes were challenged with LPS, zymosan
or poly(I:C) and processed after 6 h for RT-PCR analysis
of TLR gene expression. LPS significantly diminished
TLR4 mRNA in both astrocyte populations, while24 h in purified rat cortical microglia and enriched, but not
Astrocytes (pg IL-1β/well)
L-LME - - - L-LME
6 h 24 h 24 h
4.1 37.6 ± 1.3 66.4 ± 2.0 41.5 ± 2.0
162.4 154.4 ± 26.7 6636.9 ± 285.5 155.0 ± 17.6
742.0 186.5 ± 15.8 7081.9 ± 405.1 157.3 ± 15.2
96.8 138.5 ± 4.3 3174.6 ± 151.7 62.6 ± 0.7
ed with LPS (100 ng/ml), zymosan (10 μg/ml) or poly(I:C) (50 μg/ml) and
± SEM (n = 3). Note the lack of astrocyte responsiveness after L-LME. Values for
llular values (not shown)
Table 4 TLR agonists up-regulate IL-6 release at 6 and 24 h in purified rat cortical microglia and enriched, but not microglia-
depleted, astrocytes
Treatment Microglia (pg IL-6/well) Astrocytes (pg IL-6/well)
- - - L-LME - - - L-LME
6 h 24 h 6 h 6 h 24 h 24 h
Control 0 0 0 0 3.5 ± 3.5 0
LPS 26.3 ± 3.1 34.4 ± 0.2 75.5 ± 3.1 0 123.0 ± 1.6 4.3 ± 2.2
Zymosan 29.3 ± 0.8 64.5 ± 4.3 90.4 ± 3.5 0 130.3 ± 4.3 5.5 ± 2.9
Poly(I:C) 12.0 ± 1.5 23.4 ± 2.3 49.7 ± 2.0 0 79.1 ± 3.6 7.7 ± 4.6
Purified microglia and enriched or purified (L-LME-treated) astrocytes were challenged with LPS (100 ng/ml), zymosan (10 μg/ml) or poly(I:C) (50 μg/ml) and
processed after 6 and 24 h for IL-6 release into the culture medium by ELISA. Data are means ± SEM (n = 3). Note the lack of astrocyte responsiveness after L-LME.
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left column). Likewise, zymosan and poly(I:C) each re-
duced the TLR4 mRNA level, while raising TLR2 and
TLR3 mRNA (Fig. 8, middle and right columns, respect-
ively). Qualitatively similar trends were observed at 24 h
(data not shown). In all cases, mRNA levels were lower
in purified astrocytes, possibly indicative of removal of
the residual microglia subset. However, this explanationFig. 3 TLR agonists up-regulate pro-inflammatory cytokine gene expression
purified (L-LME-treated) astrocytes were challenged with LPS (100 ng/ml), z
IL-1β, IL-6 and TNF-α mRNA expression by RT-PCR. Data are means ± SEM (
experiments. *p < 0.05 and ***p < 0.001 vs control (‘Ctr’). For L-LME-trea
LME/agonist’ groups were noted only in two cases, as indicated by the
24 h, although relative mRNA levels were loweralone appears insufficient to fully account for these re-
sponses as, for example, the increase in TLR3 mRNA in-
duced by all three TLR ligands is at variance with the lack
of change in LPS- and poly(I:C)-treated microglia (Figs. 4,
5 and 6). These last findings suggest that either astrocytes
are more responsive in the presence of microglia or the
small numbers of contaminating microglia exhibit altered
behaviours in the presence of astrocytes [7, 8, 25, 29].in enriched but not in purified rat cortical astrocytes. Enriched or
ymosan (10 μg/ml) or poly(I:C) (50 μg/ml) and processed after 6 h for
n = 3) normalized to GAPDH levels and are representative of three
ted cultures, significant differences between the ‘L-LME’ and ‘L-
bar (*p < 0.05). Qualitatively similar results were obtained after
Fig. 4 LPS regulates TLR2, TLR3 and TLR4 mRNA expression in rat cortical microglia. Cells were incubated with 100 ng/ml LPS for 6 or 24 h and
then processed for RT-PCR analysis. Data are means ± SEM (n = 3) normalized to GAPDH levels and are representative of three experiments.
***p < 0.001 vs control (‘Ctr’)
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cortical microglia and astrocytes
After treatment of purified microglia and astrocyte
cultures with TLR agonists, the change in TLR ex-
pression level was defined by FCM using untreated
cultures (Ctr 10 % FBS) as reference (Figs. 9 and 10).
Based on MFI values of each TLR and corresponding
II AB-matched negative control detected in resting
(Figs. 9a and 10a) and primed (data not shown) cells,
we compared each pair of relative MFI values to de-
fine ratio values (Figs. 9b and 10b) as indicators of
TLR expression change induced by treatment. A com-
plex pattern of regulation was observed in purified
cortical microglia: LPS treatment significantly down-
regulated surface expression of TLR2, TLR4 at all
time points (1, 6, 24 h) examined (Fig. 9b). Zymosan
caused a transient (1 h) increase in TLR2 and TLR4;the former was significantly lower at 24 h. Much like
LPS, poly(I:C) treatment led to a significant reduction
in all three TLRs at both 6 and 24 h, with a transient
rise only in intracellular TLR3.
Astrocytes, nominally free of microglia likewise dis-
played a complex yet distinct set of responses to the
three TLR ligands: LPS treatment did not affect TLR4
expression at any time point, while significantly down-
regulating TLR3 at all times (1, 6, 24 h) and TLR2 only
at 24 h (Fig. 10b). In contrast, zymosan significantly
down-regulated TLR4 at all time points but TLR2 only
at 24 h; intracellular TLR3 was not affected over the 24-
h period. Poly(I:C) treatment variably increased expres-
sion of the TLRs at 6, 24, and 1 and 6 h, respectively, for
TLR2, TLR3 and TLR4 (Fig. 10b).
One needs to keep in mind that fluorescence intensity
values for control and TLR agonist-treated cells are
Fig. 5 Zymosan regulates TLR2, TLR3 and TLR4 mRNA expression in rat cortical microglia. Cells were incubated with 10 μg/ml zymosan for 6 or
24 h and then processed for RT-PCR analysis. Data are means ± SEM (n = 3) normalized to GAPDH levels and are representative of three
experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 vs control (‘Ctr’)
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the shift in intensity between isotype/II antibody-matched
control and sample of interest is ≥4 fluorescence intensity
values, the sample is considered positive. The stronger ex-
pression of all three TLRs on resting microglia was dem-
onstrated by a MFI difference of ~600 between positive
and negative samples and by a percentage of positive cells
for each target marker of ≥75 %. In contrast, the ex-
pression of TLR4, TLR3 and TLR2 was lower in as-
trocytes, in accordance with several studies performed
in vitro and in vivo on glial cells [39, 40]. The differ-
ence in MFI fluorescence intensity between target and
control samples ranged from 90 to 257, and the per-
centage of positive cells was 90 % for TLR3 and 20 %
for TLR4 and TLR2.NF-κB role in TLR agonist regulation of TLR subtype gene
expression in purified cortical microglia and astrocytes
LPS interaction with TLR4 activates downstream
mitogen-activated protein kinase (MAPK) and NF-κB
signalling pathways and subsequently causes inflamma-
tory mediator production [41–44]. To examine a pos-
sible role for these pathways in the regulation of TLR
transcripts by LPS, the experiments described in Figs. 4
and 8 were repeated, using the NF-κB inhibitor Ro-106-
9920. Incubation of microglia with 1 μM Ro-106-9920
reduced, by almost 90 %, the LPS-induced increases in
TNF-α mRNA and TNF-α release after 6 h (Additional
file 1: Figure S2); Ro-106-9920 (10 μM) also reduced, to
a similar extent, the LPS-mediated rise in TNF-α gene
expression in purified astrocytes (data not shown).
Fig. 6 Poly(I:C) regulates TLR2, TLR3 and TLR4 mRNA expression in rat cortical microglia. Cells were incubated with 50 μg/ml poly(I:C) for 6 or
24 h and then processed for RT-PCR analysis. Data are means ± SEM (n = 3) normalized to GAPDH levels and are representative of three
experiments. **p < 0.01 and ***p < 0.001 vs control (‘Ctr’)
Marinelli et al. Journal of Neuroinflammation  (2015) 12:244 Page 11 of 20NF-κB appeared to play a role in microglial TLR gene
expression, as Ro-106-9920 selectively influenced TLR
mRNA levels in the absence and presence of ligand
(Fig. 11). Because microglia vitality was sensitive to pro-
longed incubation with Ro-106-9920 above 3 μM in
serum-containing medium, the experiments were carried
out both in serum-containing (panels a–c) and serum-
free (panels d–f ) media. Incubation with LPS for 6 h
strongly reduced TLR4 mRNA levels in microglia
(Fig. 11a, d; see also Fig. 4); Ro-106-9920 neither altered
this effect nor influenced basal TLR4 gene expression. In
contrast, the NF-κB inhibitor markedly inhibited (≥90 %)
the LPS-induced rise in TLR2 mRNA (Fig. 11b, e); basal
TLR2 gene expression was not significantly changed. In
the case of TLR3, LPS did not influence mRNA levelsper se at 6 h (see also Fig. 4), although incubation with
Ro-106-9920 produced a robust and significant drop in
TLR3 gene expression (Fig. 9c, f ). Overall, microglial cell
behaviours were qualitatively similar independent of the
presence of serum. Ro-106-9920 likewise blocked, by
more than 85 %, the LPS-induced increase in TLR2
mRNA in purified astrocytes at 6 h (Fig. 12). However,
Ro-106-9920 did not effect any consistent alterations in
either TLR3 or TLR4 mRNA levels in astrocytes, irre-
spective of stimulation with LPS (data not shown).
Discussion
Toll-like receptors play a fundamental role in recogniz-
ing pathogens and initiating an innate immune response
to protect the host. However, sterile inflammation can
Fig. 7 Analysis of TLR4, CD14 and MD2 expression in enriched and L-LME-purified astrocytes. a Western blots show comparable levels of TLR4,
CD14 and MD2 in both astrocyte populations. Left panel: representative immunoblot. Right panel: Mean values from duplicate samples. b Confocal
microscopy shows co-expression of GFAP (green) and TLR4 (red) in enriched (L-LME-) as well as in purified (L-LME+) astrocytes. Lower frame in
each case illustrates GFAP/TLR4 overlap. Nuclei are labelled with DAPI (blue). c LPS conjugated with Alexa Fluor® 594 (red) co-localizes with GFAP
(green) in L-LME-purified astrocytes after 30 min of treatment (arrow). Nuclei are labelled with DAPI
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Fig. 8 TLR agonists regulate TLR2, TLR3 and TLR4 gene expression in rat cortical astrocytes. Enriched or purified (L-LME-treated) astrocytes were
challenged with LPS (100 ng/ml), zymosan (10 μg/ml) or poly(I:C) (50 μg/ml) and processed after 6 h for TLR2, TLR3 and TLR4 mRNA expression
by RT-PCR. Data are means ± SEM (n = 3) normalized to GAPDH levels and are representative of three experiments. *p < 0.05, **p < 0.01 and
***p < 0.001 vs control (‘Ctr’). §§p < 0.01 and §§§p < 0.001 vs L-LME-treated cells. Qualitatively similar results were obtained after 24 h, although
relative mRNA levels were lower
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age bind endogenous ligands released by stressed or in-
jured cells [45]. Not only immune system-related cells but
also CNS neuronal and non-neuronal cell types (including
microglia and astrocytes) express and respond to TLR
ligation [15, 18, 45, 46]. For microglia, these behaviours
include the output of pro-inflammatory cytokines follow-
ing stimulation with TLR2/3/4 agonists ([7, 8, 18, 47],
among others). The present study describes a novel re-
sponse of microglia to TLR ligands, namely, the ability of
these agents to induce homologous and heterologous
changes in both TLR gene expression and cell surface
TLR2/4 or intracellular TLR3 expression. Further, nomin-
ally microglia-free astrocytes, which do not respond to
TLR agonists in terms of pro-inflammatory mediator pro-
duction [7, 8, 25], remained responsive to TLR ligand
challenge in terms of altered TLR alterations, as for
microglia.
TLR activation is receiving increasing attention as be-
ing implicated in neurodegenerative disorders [19, 20],
as well as in inflammatory pain and neuropathic pain
[21–24, 46, 48]. Primary cultures of CNS-derived micro-
glia and astrocytes have found widespread applicationfor investigating the molecular events underlying TLR
actions. However, the cell preparative methodologies
currently used, while capable of yielding quite pure pop-
ulations of microglia, result in astrocytes which generally
contain a minor subset (up to 5 %) of contaminating
microglia [26, 28, 49, 50]. A number of recent studies
have highlighted the need for caution in interpreting ob-
servations made with such astrocyte cultures [7, 8, 25,
28, 29]. Our observations confirm that L-LME-mediated
eradication of the residual microglia effectively negated
astrocyte responses to TLR2/3/4 ligands in terms of IL-
1β, IL-6 and TNF-α gene induction. Yet, purified astro-
cytes appeared to express TLR4, CD14 and MD2 by
Western blot, and confocal microscopy revealed co-
expression of GFAP and TLR4 in these cells. Moreover,
fluorescently conjugated LPS underwent binding and
transport in astrocytes and co-localized with GFAP.
Thus, astrocytes have the capability to recognize this
TLR4 ligand.
The observation that TLR agonists are capable of in-
fluencing gene expression not only for their cognate re-
ceptor but also for other TLRs, in both microglia and
astrocytes, was somewhat unexpected. The TLR2/3/4
Fig. 9 TLR ligands influence expression of their receptors in purified microglia. Microglia were challenged with LPS (100 ng/ml), zymosan (10 μg/
ml) or poly(I:C) (50 μg/ml) for 1, 6 and 24 h then processed for flow cytometric analysis, as described in ‘Methods’. Based on MFI values of each
TLR and corresponding II AB-matched negative control from resting (a) and primed cells, we compared to each other the relative MFI values [MFI
TLR expression/MFI II AB-matched sample] to define ratio values [relative MFI (primed cells)/relative MFI (resting cells)] (b) as indicators of TLR
expression change induced by treatment. Data are mean ± SD of three independent experiments conducted in duplicate. *p < 0.05 and **p < 0.01
vs control
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ively) decreased TLR2 and TLR4 mRNA, while LPS and
zymosan (but not poly(I:C) decreased TLR3 transcript
levels at 24 h only. Apart from a report describing that
cell wall components derived from Gram-negative bac-
teria induce TLR2 gene in the CNS [51], other studies
dealing with TLR ligand effects on cognate receptor ex-
pression have generally been carried out in non-neural
cell types, such as human aortic smooth muscle cells
[52], cardiomyoblasts [53] and dendritic cells [54] and
TLR2. In Laflamme et al. [51], peptidoglycan, a TLR2
ligand derived from Gram-negative bacteria failed to
alter TLR2 expression. Olson and Miller [18] observed
an increased expression of TLR2 and TLR4 (but not
TLR3) mRNA in LPS (5 μg/ml)-treated mouse microglia
after 7 h. Several other reports have examined the effects
of TLR ligands on TLR expression in glia, although dif-
ferences are to be found with the present data. Such dif-
ferences include the use of astrocytes less pure than ours
[39, 55, 56], lack of comparison with microglia [56], the
use of a microglial cell line instead of primary cells [57],
lack of analysis by flow cytometry [56, 57] and use of
LPS only and not other TLR ligands [56]. As such, even
a small percentage of contaminating microglia couldaccount for the expression of TLRs observed in astrocyte
cultures. Further, it is well-documented that established
protocols for isolating LPS result in the co-purification
of varying amounts of endotoxin protein(s) such as lipo-
proteins [58, 59] (addressed at length in [58] and refer-
ences within). As these contaminants possess potent
bioactivity, assigning cellular responses to the LPS com-
ponent of a particular preparation may be confounded
by the presence of these contaminants which could be
responsible for the TLR2-mediated signalling observed
upon LPS stimulation. The relatively high concentrations
(5–25 μg/ml) of LPS used in several of the above studies
[55, 56], together with a lack of information as to LPS
purity needs to be considered when interpreting the
data. We also performed an experiment comparing the
biological activity LPS from E. coli 026:B6 (Sigma) with
LPS-EB Ultra-Pure (InvivoGen) in the presence of poly-
myxin B, which competes with LPS for binding to (and
activation of ) TLR4. LPS (InvivoGen) activity in terms of
IL-1β release and nitric oxide production from rat
cortical microglia, used at 1000 ng/ml, was fully blocked
by polymyxin B—in contrast to LPS from Sigma
(Additional file 1: Figure S4). Therefore, the Sigma LPS
contains LPS-independent activity.
Fig. 10 TLR ligands influence expression of their receptors in purified astrocytes. Purified (L-LME-treated) astrocytes were challenged with LPS
(100 ng/ml), zymosan (10 μg/ml) or poly(I:C) (50 μg/ml) for 1, 6 and 24 h then processed for flow cytometric analysis, as described in ‘Methods’.
Based on MFI values of each TLR and corresponding II AB-matched negative control detected in resting (a) and primed cells, we compared the
relative MFI values [MFI TLR expression/MFI II AB-matched sample] to define ratio values [relative MFI (primed cells)/relative MFI (resting cells)]
(b) as indicators of TLR expression change induced by treatment. Data are mean ± SD of three independent experiments conducted in duplicate.
**p < 0.01 vs control
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8 induced IL-1β in astrocytes, although cells were only
95 % pure [60]. Surface expression of TLR2 and TLR4,
and intracellular expression of TLR3, was consistently
reduced in microglia by LPS and poly(I:C). On the other
hand, changes induced by zymosan were more variable.
Astrocyte responses to LPS, zymosan and poly(I:C) were
substantially like those of microglia, with all three ago-
nists down-regulating TLR4 transcripts, while up-
regulating TLR2. In contradistinction to microglia, these
TLR ligands up-regulated TLR3 mRNA in astrocytes. In
general, the relative levels of TLR mRNA were lower in
purified (L-LME-treated) astrocytes. While the latter ob-
servation is likely to reflect removal of contaminating
microglia, the behaviour of TLR3 mRNA in astrocytes
contrasts with a lack of change in this TLR for LPS- and
poly(I:C)-treated microglia. Conceivably, astrocytes may
be more responsive in the presence of microglia, or the
small numbers of residual microglia could behave differ-
ently in the presence of astrocytes [7, 8, 18, 29]. Further
studies will be needed to shed more light on this ques-
tion. Although outside the scope of the present study, it
will be interesting to explore possible developmentalconsiderations regarding microglia and astrocyte sensi-
tivity to TLR stimulation.
Ligand-regulated TLR expression is likely to be a
complex process, especially when cross-TLR expression
is involved. Indeed, changes in TLR expression, as deter-
mined by qRT-PCR and FCM did not agree with each
other in several instances. A discrepancy between qPCR
and corresponding protein expression has already been
reported [39] and could be justified considering two dif-
ferent regulatory levels of TLR signalling. On the one
hand, activation of MyD88-dependent and MyD88-
independent pathways after agonist stimulation pro-
motes increased expression of TLR target genes [39, 61].
Up-regulation of TLR2 mRNA is considered consequent
to the activation of pro-inflammatory signalling [62], as
TLR2 is a target gene of NF-κB. On the other hand, the
level of TLR membrane expression is subject to regula-
tion in order to tune cellular responsiveness to bacterial,
fungal and viral insults and to reduce/increase the acti-
vation of microglia and astrocytes. Such expression may
differ for a given cell type as a function of species,
maturation and activation state, and is known to be
modified by positive and negative feedback mechanisms
Fig. 11 The NF-κB inhibitor Ro-106-9920 alters TLR gene expression rat cortical microglia. Cells were first incubated 30 min with 1 μM (a–c) or
3 μM (d–f) Ro-106-9920 (‘Ro-106’) in serum-free and serum-containing medium, respectively, followed by addition of LPS to a final concentration
of 100 ng/ml LPS. After a further 6 h, cells were collected and processed for RT-PCR analysis. TLR4 (a, d); TLR2 (b, e); TLR3 (c, f). Data are means ±
SEM (n = 3) normalized to GAPDH levels. a **p < 0.01 for LPS vs Ctr and LPS + Ro-106-9920 vs Ctr; b *p < 0.05 for LPS vs Ctr and §§p < 0.01 for LPS
vs Ro-106-9920; c ***p < 0.001 for Ro-106-9920 vs Ctr and LPS + Ro-106-9920 vs Ctr, and §§p < 0.01 for LPS vs LPS + Ro-106-9920; e **p < 0.01 for
LPS vs Ctr and §§§p < 0.001 for LPS vs LPS + Ro-106-9920; f *p < 0.05 for LPS + Ro-106-9920 vs Ctr. Similar results were obtained in a second
experiment
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tive regulation by pro-inflammatory cytokines [65] and
endocytic pathways [66]. After bacterial insults, astro-
cytes and microglia are spared from hypersensitivity
through LPS-mediated endocytosis of TLRs or negative
regulatory mechanisms [63]. In L-LME-treated astro-
cytes stimulated with Ultra-Pure LPS, membrane TLR2
expression was unchanged from 1 to 6 h but down-
regulated at 24 h. In contrast, TLR4 expression wasunaffected. Prior exposure to LPS reportedly induces a
transient state of endotoxin tolerance (cell refractori-
ness) to LPS re-stimulation which correlates with re-
duced cell surface expression of the LPS receptor
complex (TLR4/MD-2) or with other inhibitory mecha-
nisms downstream of TLR4/MD-2. In the present study,
analysis of TLRs on glial cells suggested that purified as-
trocytes retain their surveillance activity against a spe-
cific stimulus without changing expression of the related
Fig. 12 The NF-κB inhibitor Ro-106-9920 blocks LPS-induced up-
regulation of TLR2 gene expression in rat cortical astrocytes. Purified
(L-LME-treated) astrocytes were first incubated 30 min with 10 μM
Ro-106-9920 (‘Ro-106’) in serum-containing medium, followed by
addition of LPS to a final concentration of 100 ng/ml LPS. After a
further 6 h, cells were collected and processed for TLR2 mRNA
expression by RT-PCR. Data are means ± SEM (n = 3) normalized to
GAPDH levels. ***p < 0.001 for LPS vs Ctr; §§§p < 0.001 for LPS vs LPS
+ Ro-106-9920. Similar results were obtained in a second experiment
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rather induce tolerance to other stimuli by decreasing
expression of their corresponding receptor.
It is important to keep in mind that the aim of this
study was to define cell responsiveness to TLR ligands;
thus, we used flow cytometry analysis on non-
permabilized samples to detect plasma membrane-
exposed TLR2 and TLR4. Different types of information
are derived from FCM, immunofluorescence and
Western blot. FCM permits one to quantify the expres-
sion of target proteins using a defined cell number,
whereas immunofluorescence allows for the detection of
TLR4 distribution together with GFAP in one region of
interest of limited area. Moreover, Western blot analysis
was performed using 10 μg total proteins from each
sample (corresponding to 250,000 cells—far greater than
the 10,000 cells routinely used for FCM analysis). In
order to detect and better quantify minimal changes in
the expression of TLRs upon treatment with LPS,
poly(I:C) or zymosan, FCM was preferred to Western
blotting because the former is a rapid and reliable
method offering high sensitivity of detection compared
to alternative methods [67]. Due to this higher sensitivity
in detecting minimal differences among samples and
cells of heterogenous samples, FCM is used instead of
Western blotting at the clinical level as an elective
method for microbiological studies [68], immunopheno-
typing of haematological disorders [69] and monitoringof HIV-infected patients [70]. Moreover, in several stud-
ies on TLR signalling during the immune response of
microglia and astrocytes performed using FCM com-
bined with qPCR, FCM data were not confirmed by
Western blot [39, 55, 71], perhaps as a consequence of
differences in sample preparation which maintains con-
formational epitope(s) in FCM but results in its destruc-
tion in Western blot. Flow cytometry as well allows one
to analyse target markers considering a defined number
of cells and to correlate the expression of TLRs with the
physical parameters (cell size and complexity) of each
glial cell subset.
Activation of the p38 MAPK/NF-κB signalling cascade
by ligand engagement of TLR2 and TLR4 is central to
the production of pro-inflammatory cytokines such as
TNF-α and a number of interleukin family members.
Interestingly, an established NF-κB inhibitor was effica-
cious in blocking LPS-induced up-regulation of TLR2
mRNA in both purified microglia and astrocytes. The
p65 subunit of NF-κB is a substrate for p38 [72], and the
p38 inhibitor SB-202190 was also efficacious in substan-
tially blocking the LPS effects on TLR2 (and TNF-α)
gene expression in both cell populations (Marinelli and
Skaper, unpublished observations). A more complete
elucidation of the molecular components involved in
this action awaits further studies.
TLR2 and TLR4 activation in particular, in concert
with microglia and astrocytes, comprise key elements
in the initiation and maintenance of neuropathic pain
[48, 73–76]. The finding that both homologous (zy-
mosan) and heterologous (LPS, poly(I:C)) TLR ligands
are capable of regulating TLR2 gene expression may
have important implications in understanding the
relative contributions of different TLRs in neuro-
logical disorders associated with neuroinflammation.
Conclusions
The present study is the first to examine the regulation
of various TLR subtype genes as a consequence of TLR
signalling in purified microglia and astrocytes, two cell
types implicated in the initiation and maintenance of
neuroinflammation. In particular, our findings have
isolated independent contributions of TLR stimulation
on astrocytes and microglia. These observations may
have important implications in understanding the
participation of different TLRs in pain and other neuro-
logical disorders.
Additional file 1
Additional file 1: Figure S1–S4. Figure S1 L-leucyl-L-leucine methyl
ester (L-LME) depletes enriched astrocytes of microglia. Following
mechanical separation of microglia from the mixed glial cell monolayers,
astrocytes were detached, replated, and incubated the next day with
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and processed 24 h later for Iba1 mRNA by RT-PCR. L-LME- treated
astrocytes displayed an Iba1 mRNA level of 0.17-fold difference compared
to enriched (≥95 %) astrocytes. Parallel sets of cultures were processed
for GFAP (red) and Iba1 (green) immunocytochemistry (lower panels).
Nuclei are labelled blue with DAPI. Note the loss of residual microglia
(arrows) in the L-LME-treated culture. Figure S2 The NF-κB inhibitor
Ro-106-9920 blocks LPS-induced TNF-α gene and protein expression in
purified rat cortical microglia. Cells were pretreated 30 min with 1 μM
Ro-106-9920 (‘Ro-106’), followed by addition of LPS (100 ng/ml final) and
incubation continued for a further 6 h. Cells were then collected and
processed for mRNA analysis by RT-PCR (left panel) and culture medium
for TNF-α content by ELISA (right panel). Values are means ± s.e.m. (n = 3).
***p < 0.001 for LPS vs Ctr or Ro-106-9920; §§§p < 0.001 for LPS vs LPS +
Ro-106-9920. Figure S3 Western blot analysis of TLR2, TLR3 and TLR4
expression in purified rat cortical microglia. Cell lysates were prepared
from 10,000 cells and probed for the indicated TLR as described in
Methods. This number of microglia corresponds to their expected
contribution in 250,000 enriched astrocytes analysed in Fig. 7a. As can
be seen. This number of microglia is insufficient to produce a signal.
Figure S4 Effect of polymyxin B on nitric oxide production and IL-1β
release from rat cortical microglia stimulated with different commercial
sources of LPS. Purified microglia were challenged with LPS (1 μg/ml)
obtained from Sigma (<5 % protein impurities) or InivoGen (LPS-EB Ultra-
Pure). Where indicated, the LPS antagonist polymyxin B was included in
the culture (10 μg/ml). Cell culture medium was collected after 24 h and
processed for IL-1β content by ELISA. Data are means ± SEM (n = 3). Note
the lack of cell responsiveness to LPS-EB (but not LPS from Sigma) in the
presence of polymyxin B. (DOC 3981 kb)
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